Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Chien, Wen, Kuo-Chang, Sung, Pi-Lin, Chou, Yu-Ting, Liew, Phui-Ly, Chen, Lin-Yu, Huang, Rui-Lan, Lai, Hung-Cheng, Chang, Lu-Te
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725117/
https://www.ncbi.nlm.nih.gov/pubmed/33292376
http://dx.doi.org/10.1186/s13048-020-00751-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725117/
https://www.ncbi.nlm.nih.gov/pubmed/33292376
http://dx.doi.org/10.1186/s13048-020-00751-3

Ejemplares similares